Literature DB >> 3949288

Extrasellar prolactinomas: successful management of 24 patients using bromocriptine.

J O Sieck, N L Niles, J R Jinkins, O Al-Mefty, S el-Akkad, N Woodhouse.   

Abstract

24 patients with an extrasellar prolactinoma (mean prolactin 4,722 ng/ml), 8 of whom had previously had surgery, received 5-40 mg bromocriptine daily for 13-252 weeks. The mean prolactin level had fallen 89% at 2 days, 95% at 6 weeks, and 15 patients achieved normal values. Tumor shrinkage occurred in all 9 patients rescanned within 2 weeks and later was documented in 23; in 18 the extrasellar tumour disappeared. 12 patients had visual abnormalities; 7, including 2 who had been completely blind, improved within 1 week. 2 patients had normal prolactin levels after withdrawal of bromocriptine, 1 following radiotherapy and the other during two uncomplicated pregnancies. Bromocriptine is safe and effective. We conclude that medical treatment should always precede surgery unless pituitary apoplexy causes sudden deterioration of vision. Most patients will subsequently require radiotherapy or surgery for permanent cure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3949288     DOI: 10.1159/000180318

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  4 in total

1.  Combined treatment of invasive giant prolactinomas.

Authors:  Chonjiang Yu; Zhebao Wu; Jian Gong
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Surgical management of giant pituitary tumours--a review of 30 cases.

Authors:  A Goel; T Nadkarni
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

3.  Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.

Authors:  John R Lindsay; Janet A Harding; Peter K Ellis; Brian Sheridan; A Brew Atkinson
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

4.  Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.

Authors:  Zhe Bao Wu; Zhi Peng Su; Jin Sen Wu; Wei Ming Zheng; Qi Chuan Zhuge; Ming Zhong
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.